Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population.

Snauwaert E, Van Biesen W, Raes A, Glorieux G, Vande Walle J, Roels S, Vanholder R, Askiti V, Azukaitis K, Bayazit A, Canpolat N, Fischbach M, Saoussen K, Litwin M, Obrycki L, Paglialonga F, Ranchin B, Samaille C, Schaefer F, Schmitt CP, Spasojevic B, Stefanidis CJ, Shroff R, Eloot S.

Nephrol Dial Transplant. 2019 Jul 30. pii: gfz132. doi: 10.1093/ndt/gfz132. [Epub ahead of print]

PMID:
31361315
2.

Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease.

Borges Bonan N, Schepers E, Pecoits-Filho R, Dhondt A, Pletinck A, De Somer F, Vanholder R, Van Biesen W, Moreno-Amaral A, Glorieux G.

Sci Rep. 2019 Jul 15;9(1):10236. doi: 10.1038/s41598-019-46724-5.

3.

Selective Transport of Protein-Bound Uremic Toxins in Erythrocytes.

Deltombe O, Glorieux G, Marzouki S, Masereeuw R, Schneditz D, Eloot S.

Toxins (Basel). 2019 Jul 1;11(7). pii: E385. doi: 10.3390/toxins11070385.

4.

Uremic Toxin Concentrations are Related to Residual Kidney Function in the Pediatric Hemodialysis Population.

Snauwaert E, Holvoet E, Van Biesen W, Raes A, Glorieux G, Vande Walle J, Roels S, Vanholder R, Askiti V, Azukaitis K, Bayazit A, Canpolat N, Fischbach M, Godefroid N, Krid S, Litwin M, Obrycki L, Paglialonga F, Ranchin B, Samaille C, Schaefer F, Schmitt CP, Spasojevic B, Stefanidis CJ, Van Dyck M, Van Hoeck K, Collard L, Eloot S, Shroff R.

Toxins (Basel). 2019 Apr 24;11(4). pii: E235. doi: 10.3390/toxins11040235.

5.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

6.

The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds.

Perna AF, Glorieux G, Zacchia M, Trepiccione F, Capolongo G, Vigorito C, Anishchenko E, Ingrosso D.

J Nephrol. 2019 Jan 23. doi: 10.1007/s40620-019-00589-z. [Epub ahead of print] Review.

PMID:
30673975
7.

Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury.

Veldeman L, Vanmassenhove J, Van Biesen W, Massy ZA, Liabeuf S, Glorieux G, Vanholder R.

Int Urol Nephrol. 2019 Feb;51(2):293-302. doi: 10.1007/s11255-018-2056-x. Epub 2019 Jan 2.

PMID:
30604232
8.

Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease.

Chinnappa S, Tu YK, Yeh YC, Glorieux G, Vanholder R, Mooney A.

Toxins (Basel). 2018 Dec 5;10(12). pii: E520. doi: 10.3390/toxins10120520.

9.

Gut microbiota dynamics and uraemic toxins: one size does not fit all.

Joossens M, Faust K, Gryp T, Nguyen ATL, Wang J, Eloot S, Schepers E, Dhondt A, Pletinck A, Vieira-Silva S, Falony G, Vaneechoutte M, Vanholder R, Van Biesen W, Huys GRB, Raes J, Glorieux G.

Gut. 2018 Nov 21. pii: gutjnl-2018-317561. doi: 10.1136/gutjnl-2018-317561. [Epub ahead of print] No abstract available.

10.

Gut-Derived Metabolites and Chronic Kidney Disease: The Forest (F)or the Trees?

Vanholder R, Glorieux G.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1311-1313. doi: 10.2215/CJN.08200718. Epub 2018 Aug 7. No abstract available.

11.

Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Vanholder R, Van Laecke S, Glorieux G, Verbeke F, Castillo-Rodriguez E, Ortiz A.

Toxins (Basel). 2018 Jun 12;10(6). pii: E237. doi: 10.3390/toxins10060237. Review.

12.

Increased urinary osmolyte excretion indicates chronic kidney disease severity and progression rate.

Gil RB, Ortiz A, Sanchez-Niño MD, Markoska K, Schepers E, Vanholder R, Glorieux G, Schmitt-Kopplin P, Heinzmann SS.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2156-2164. doi: 10.1093/ndt/gfy020.

PMID:
29554320
13.

A plea for more uremic toxin research in children with chronic kidney disease.

Snauwaert E, Van Biesen W, Raes A, Glorieux G, Vanholder R, Vande Walle J, Eloot S.

Pediatr Nephrol. 2018 Jun;33(6):921-924. doi: 10.1007/s00467-018-3920-8. Epub 2018 Mar 2. No abstract available.

PMID:
29500629
14.

Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Vanholder R, Pletinck A, Schepers E, Glorieux G.

Toxins (Basel). 2018 Jan 8;10(1). pii: E33. doi: 10.3390/toxins10010033. Review.

15.

Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up.

Schepers E, Glorieux G, Eloot S, Hulko M, Boschetti-de-Fierro A, Beck W, Krause B, Van Biesen W.

BMC Nephrol. 2018 Jan 5;19(1):1. doi: 10.1186/s12882-017-0808-y.

16.

p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky.

Evenepoel P, Glorieux G, Meijers B.

Kidney Int. 2017 Dec;92(6):1323-1324. doi: 10.1016/j.kint.2017.06.029.

PMID:
29153138
17.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

18.

Genetic evaluation for birth and conformation traits in dual-purpose Belgian Blue cattle using a mixed inheritance model.

Mota RR, Mayeres P, Bastin C, Glorieux G, Bertozzi C, Vanderick S, Hammami H, Colinet FG, Gengler N.

J Anim Sci. 2017 Oct;95(10):4288-4299. doi: 10.2527/jas2017.1748.

PMID:
29108034
19.

Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.

Eloot S, Van Biesen W, Roels S, Delrue W, Schepers E, Dhondt A, Vanholder R, Glorieux G.

PLoS One. 2017 Oct 10;12(10):e0186010. doi: 10.1371/journal.pone.0186010. eCollection 2017.

20.

Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population.

Snauwaert E, Van Biesen W, Raes A, Glorieux G, Van Bogaert V, Van Hoeck K, Coppens M, Roels S, Vande Walle J, Eloot S.

Nephrol Dial Transplant. 2018 Jun 1;33(6):978-986. doi: 10.1093/ndt/gfx224.

PMID:
28992139
21.

p-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance.

Koppe L, Alix PM, Croze ML, Chambert S, Vanholder R, Glorieux G, Fouque D, Soulage CO.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2000-2009. doi: 10.1093/ndt/gfx089.

PMID:
28992089
22.

Binding of bromocresol green and bromocresol purple to albumin in hemodialysis patients.

Delanghe S, Biesen WV, Velde NV, Eloot S, Pletinck A, Schepers E, Glorieux G, Delanghe JR, Speeckaert MM.

Clin Chem Lab Med. 2018 Feb 23;56(3):436-440. doi: 10.1515/cclm-2017-0444.

PMID:
28985181
23.

Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.

Snauwaert E, Van Biesen W, Raes A, Holvoet E, Glorieux G, Van Hoeck K, Van Dyck M, Godefroid N, Vanholder R, Roels S, Walle JV, Eloot S.

Pediatr Nephrol. 2018 Feb;33(2):315-323. doi: 10.1007/s00467-017-3802-5. Epub 2017 Sep 22.

PMID:
28939943
24.

The Place of Large Pore Membranes in the Treatment Portfolio of Patients on Hemodialysis.

Van Biesen W, Vanholder R, Schepers E, Glorieux G, Dhondt A, Eloot S.

Contrib Nephrol. 2017;191:168-177. doi: 10.1159/000479265. Epub 2017 Sep 14. Review.

PMID:
28910800
25.

Quantification of carbamylated albumin in serum based on capillary electrophoresis.

Delanghe S, Moerman A, Pletinck A, Schepers E, Glorieux G, Van Biesen W, Delanghe JR, Speeckaert MM.

Electrophoresis. 2017 Sep;38(17):2135-2140. doi: 10.1002/elps.201700068. Epub 2017 Jun 30.

PMID:
28556931
26.

Exploring binding characteristics and the related competition of different protein-bound uremic toxins.

Deltombe O, de Loor H, Glorieux G, Dhondt A, Van Biesen W, Meijers B, Eloot S.

Biochimie. 2017 Aug;139:20-26. doi: 10.1016/j.biochi.2017.05.010. Epub 2017 May 17.

PMID:
28528271
27.

Early and asymptomatic cardiac dysfunction in chronic kidney disease.

Chinnappa S, White E, Lewis N, Baldo O, Tu YK, Glorieux G, Vanholder R, El Nahas M, Mooney A.

Nephrol Dial Transplant. 2018 Mar 1;33(3):450-458. doi: 10.1093/ndt/gfx064.

28.

Urea and chronic kidney disease: the comeback of the century? (in uraemia research).

Vanholder R, Gryp T, Glorieux G.

Nephrol Dial Transplant. 2018 Jan 1;33(1):4-12. doi: 10.1093/ndt/gfx039. Review.

PMID:
28407121
29.

Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study.

Van Laecke S, Kerre T, Nagler EV, Maes B, Caluwe R, Schepers E, Glorieux G, Van Biesen W, Verbeke F.

Nephrol Dial Transplant. 2018 Mar 1;33(3):489-496. doi: 10.1093/ndt/gfx040.

PMID:
28387829
30.

p-Cresyl Sulfate.

Gryp T, Vanholder R, Vaneechoutte M, Glorieux G.

Toxins (Basel). 2017 Jan 29;9(2). pii: E52. doi: 10.3390/toxins9020052. Review.

31.

Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study.

Boelaert J, Lynen F, Glorieux G, Schepers E, Neirynck N, Vanholder R.

Anal Bioanal Chem. 2017 Mar;409(8):2201-2211. doi: 10.1007/s00216-016-0165-x. Epub 2017 Jan 12.

PMID:
28083662
33.

New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma.

Pavlenko D, van Geffen E, van Steenbergen MJ, Glorieux G, Vanholder R, Gerritsen KG, Stamatialis D.

Sci Rep. 2016 Oct 5;6:34429. doi: 10.1038/srep34429.

34.

Intestinal metabolites, chronic kidney disease and renal transplantation: Enigma Variations?

Vanholder R, Glorieux G, Massy ZA.

Nephrol Dial Transplant. 2016 Oct;31(10):1547-51. doi: 10.1093/ndt/gfw040. Epub 2016 Apr 6. No abstract available.

PMID:
27190337
35.

Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.

Boelaert J, Schepers E, Glorieux G, Eloot S, Vanholder R, Lynen F.

Toxins (Basel). 2016 May 13;8(5). pii: E149. doi: 10.3390/toxins8050149.

36.

Disruption, but not overexpression of urate oxidase alters susceptibility to pentylenetetrazole- and pilocarpine-induced seizures in mice.

Thyrion L, Portelli J, Raedt R, Glorieux G, Larsen LE, Sprengers M, Van Lysebettens W, Carrette E, Delbeke J, Vonck K, Boon P.

Epilepsia. 2016 Jul;57(7):e146-50. doi: 10.1111/epi.13410. Epub 2016 May 9.

37.

Development of a MALDI MS-based platform for early detection of acute kidney injury.

Carrick E, Vanmassenhove J, Glorieux G, Metzger J, Dakna M, Pejchinovski M, Jankowski V, Mansoorian B, Husi H, Mullen W, Mischak H, Vanholder R, Van Biesen W.

Proteomics Clin Appl. 2016 Jul;10(7):732-42. doi: 10.1002/prca.201500117. Epub 2016 May 17.

38.

Clinical management of the uraemic syndrome in chronic kidney disease.

Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, Massy ZA, Ortiz A, Rossignol P, Wiecek A, Zoccali C, London GM; European Renal Association European Dialysis; Transplant Association (ERA-EDTA) European Renal; Cardiovascular Medicine (EURECA-m) working group.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):360-73. doi: 10.1016/S2213-8587(16)00033-4. Epub 2016 Mar 3. Review. Erratum in: Lancet Diabetes Endocrinol. 2016 Apr;4(4):e4.

PMID:
26948372
39.

Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes.

Liabeuf S, Desjardins L, Massy ZA, Brazier F, Westeel PF, Mazouz H, Titeca-Beauport D, Diouf M, Glorieux G, Vanholder R, Jaureguy M, Choukroun G.

Circ J. 2016;80(3):722-30. doi: 10.1253/circj.CJ-15-0949. Epub 2016 Feb 4.

40.

Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis.

Eloot S, Schneditz D, Cornelis T, Van Biesen W, Glorieux G, Dhondt A, Kooman J, Vanholder R.

PLoS One. 2016 Jan 22;11(1):e0147159. doi: 10.1371/journal.pone.0147159. eCollection 2016.

41.

Uric acid is released in the brain during seizure activity and increases severity of seizures in a mouse model for acute limbic seizures.

Thyrion L, Raedt R, Portelli J, Van Loo P, Wadman WJ, Glorieux G, Lambrecht BN, Janssens S, Vonck K, Boon P.

Exp Neurol. 2016 Mar;277:244-251. doi: 10.1016/j.expneurol.2016.01.001. Epub 2016 Jan 8.

PMID:
26774005
42.

Future Avenues to Decrease Uremic Toxin Concentration.

Vanholder RC, Eloot S, Glorieux GL.

Am J Kidney Dis. 2016 Apr;67(4):664-76. doi: 10.1053/j.ajkd.2015.08.029. Epub 2015 Oct 21. Review.

PMID:
26500179
43.

Integration of external estimated breeding values and associated reliabilities using correlations among traits and effects.

Vandenplas J, Colinet FG, Glorieux G, Bertozzi C, Gengler N.

J Dairy Sci. 2015 Dec;98(12):9044-50. doi: 10.3168/jds.2015-9894.

44.

Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.

Deltombe O, Van Biesen W, Glorieux G, Massy Z, Dhondt A, Eloot S.

Toxins (Basel). 2015 Sep 28;7(10):3933-46. doi: 10.3390/toxins7103933.

45.

Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes.

Mutsaers HA, Stribos EG, Glorieux G, Vanholder R, Olinga P.

Front Med (Lausanne). 2015 Aug 31;2:60. doi: 10.3389/fmed.2015.00060. eCollection 2015. Review.

46.

Uraemic toxins and new methods to control their accumulation: game changers for the concept of dialysis adequacy.

Glorieux G, Tattersall J.

Clin Kidney J. 2015 Aug;8(4):353-62. doi: 10.1093/ckj/sfv034. Epub 2015 Jun 1.

47.

New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis.

Glorieux G, Mullen W, Duranton F, Filip S, Gayrard N, Husi H, Schepers E, Neirynck N, Schanstra JP, Jankowski J, Mischak H, Argilés À, Vanholder R, Vlahou A, Klein J.

Nephrol Dial Transplant. 2015 Nov;30(11):1842-52. doi: 10.1093/ndt/gfv254. Epub 2015 Jul 9.

PMID:
26160894
48.

Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial.

Dhondt A, Pauwels R, Devreese K, Eloot S, Glorieux G, Vanholder R.

PLoS One. 2015 Jun 15;10(6):e0128634. doi: 10.1371/journal.pone.0128634. eCollection 2015.

49.

Once upon a time in dialysis: the last days of Kt/V?

Vanholder R, Glorieux G, Eloot S.

Kidney Int. 2015 Sep;88(3):460-5. doi: 10.1038/ki.2015.155. Epub 2015 Jun 10. Review.

PMID:
26061543
50.

Protein-bound solute removal during extended multipass versus standard hemodialysis.

Eloot S, Van Biesen W, Axelsen M, Glorieux G, Pedersen RS, Heaf JG.

BMC Nephrol. 2015 Apr 18;16:57. doi: 10.1186/s12882-015-0056-y.

Supplemental Content

Loading ...
Support Center